Carl Zeiss buys IOL manufacturer Aaren Scientific

Article

Carl Zeiss Meditec AG announced it has acquired, through its subsidiary Carl Zeiss Meditec Inc., 100% of the shares in Aaren Scientific Inc., a U.S.-based manufacturer of intraocular lenses (IOLs).

Germany-Carl Zeiss Meditec AG announced it has acquired, through its subsidiary Carl Zeiss Meditec Inc., 100% of the shares in Aaren Scientific Inc., a U.S.-based manufacturer of intraocular lenses (IOLs). Aaren Scientific, headquartered in Ontario, CA, has been manufacturing IOLs for more than two decades.

The majority of shares in Aaren Scientific were owned by a private investment company as well as other investors, including the CEO and co-founder of Aaren Scientific, Rick Aguilera. Aguilera and the management team will remain after the transaction.

Aaren Scientific was the first manufacturer of IOLs in the U.S. to receive a CE registration and is well known for its innovative R&D capabilities. The company currently has 235 employees. In 2012, Aaren Scientific achieved total revenues of approximately $20 million, primarily generated outside of the U.S. The company will be integrated into the Strategic Business Unit (SBU) Surgical Ophthalmology of Carl Zeiss Meditec and complements the existing Zeiss IOL development and manufacturing sites in Berlin, Germany, and La Rochelle, France. The SBU Surgical Ophthalmology has continuously reported above market growth rates for the last 3-4 years driven by strong demand for innovative IOLs.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
© 2025 MJH Life Sciences

All rights reserved.